A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
This study is testing a medication called Migalastat (a 20 mg capsule) for children aged 2 to 11 who have Fabry disease. Specifically, it's for those with a particular genetic change that Migalastat is known to help. We want to see how safe the medicine is, how the body uses it (pharmacokinetics), what effects it has (pharmacodynamics), and if it improves the health of children with Fabry disease. The study will last for about 12 months of treatment, with an option to continue afterwards. Children joining can't have been on other Fabry treatments recently or must have stopped them. This research hopes to find a safe and effective way to manage Fabry disease in a younger age group.
Auf einen Blick
Worum geht es in dieser Studie?
Fabry disease is a rare genetic condition that can affect many parts of the body, including the kidneys, heart, and skin. It happens because the body can't make enough of a certain enzyme, which leads to a build-up of fats in cells. This can cause various health problems.
This study is looking at a medicine called Migalastat. It's designed for children aged 2 to under 12 years old who have Fabry disease, but only if they have a specific type of genetic change that Migalastat is known to work for. Think of it like a key fitting a specific lock. The main goal is to understand how safe the medicine is for these younger children, how their bodies process it, and if it helps to improve their Fabry disease symptoms over about a year.
By carefully studying Migalastat in this age group, researchers hope to gather important information that could potentially lead to it becoming a treatment option for more children with Fabry disease in the future. This is a common and important step in developing new medicines.
Wichtige Erkenntnisse
- This study evaluates Migalastat for children (2-11 years) with Fabry disease.
- It focuses on specific genetic types of Fabry disease that Migalastat can help.
- The study assesses safety, how the body handles the medicine, and its effectiveness.
- Treatment lasts about 12 months, with an option for longer-term follow-up.
- Children currently on other Fabry treatments may need to pause them before joining.
Wer könnte berechtigt sein?
This study is for boys and girls with Fabry disease who are between 2 and 11 years old. A very important part of joining is that your child must have a specific type of genetic change (called an 'amenable GLA variant') that Migalastat is designed to work with. Your child should also have experienced at least one medical issue related to their Fabry disease.
Children can't join if they have severe kidney problems or are already on dialysis. Also, if your child has an allergy to Migalastat or similar medicines, or if they are currently taking other research medicines, they wouldn't be able to participate. If your child has had gene therapy, they also can't take part. Girls and boys who are able to have children must agree to use birth control during the study and for 30 days afterwards.
Additionally, if your child has recently received (within the last 14 days) or is currently receiving other specific Fabry disease treatments like enzyme replacement therapy (ERT), they would need to stop that treatment for the required time before joining.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Is your child between 2 and 11 years old?
- Does your child have Fabry disease with a specific genetic change that Migalastat works for?
- Has your child had any health problems linked to Fabry disease?
- Does your child NOT have severe kidney problems or an allergy to Migalastat?
- Has your child NOT received gene therapy at any point?
Was beinhaltet die Teilnahme?
If your child joins, they will take Migalastat as a capsule. The study involves two treatment periods totaling about 12 months, followed by an option to continue on the medicine in an extension phase. There will be no breaks in treatment between these active phases. If your child stops taking part at any time, they will have a safety check-up 30 days later.
Throughout the study, your child will have regular visits to the clinic for medical checks. This will include blood tests to measure the level of Migalastat in their body at certain times. These blood tests are done at specific points, including four samples over a 24-hour period within the first month, and then single samples at months 6 and 12. These tests help the doctors understand how the medicine is working and how safe it is. The total duration of active treatment for initial participation is about 12 months.
Potenzielle Risiken und Vorteile
Standorte (12)
- Emory GeneticsVerifizierte PostleitzahlAtlanta, Vereinigte Staaten· Rekrutierung
- Universität von Minnesota Masonic KinderkrankenhausVerifizierte PostleitzahlMinneapolis, Vereinigte Staaten· Rekrutierung
- Atrium Health Levine Children's HospitalVerifizierte PostleitzahlCharlotte, Vereinigte Staaten· Rekrutierung
- Cincinnati Kinderkrankenhaus Medizinisches ZentrumVerifizierte PostleitzahlCincinnati, Vereinigte Staaten· Rekrutierung
- UPMC Children's Hospital of PittsburghVerifizierte PostleitzahlPittsburgh, United States· Rekrutierung
- Lysosomal and Rare Disorders Research and Treatment Center, Inc.Verifizierte PostleitzahlFairfax, Vereinigte Staaten· Rekrutierung
- Universitair Ziekenhuis (UZ) LeuvenVerifizierte PostleitzahlLeuven, Belgien· Rekrutierung
- Universitäetsklinikum Müenster (UKM) Klinik für Kinder- und Jugendmedizin - Allgemeine PaediatrieVerifizierte PostleitzahlMünster, Germany· Rekrutierung
- Kitasato University HospitalVerifizierte PostleitzahlSagamihara, Japan· Rekrutierung
- Hospital Universitario de la PazVerifizierte PostleitzahlMadrid, Spanien· Rekrutierung
- Great Ormond Street Hospital for Children NHS Foundation TrustVerifizierte PostleitzahlLondon, Vereinigtes Königreich· Noch nicht rekrutiert
- Manchester Universität NHS StiftungstrustVerifizierte PostleitzahlManchester, Vereinigtes Königreich· Rekrutierung
Häufige Fragen
What is Fabry disease?
Fabry disease is a rare genetic condition where the body can't break down certain fatty substances, leading to their build-up in cells and causing health problems in various organs.
What is Migalastat?
Migalastat is a medication that helps the body's own faulty enzyme work better in some people with Fabry disease who have a specific genetic change.
Wie lange wird mein Kind an der Studie teilnehmen?
Your child will receive Migalastat treatment for about 12 months, with the possibility of continuing in an extension phase afterwards.
Will my child have to stop their current Fabry treatment?
If your child is on enzyme replacement therapy (ERT), they would need to stop it at least 14 days before starting this study.
Can my child choose to leave the study?
Yes, you can choose to withdraw your child from the study at any time without having to give a reason, and it won't affect their future medical care.
Wie Sie mehr erfahren können
Amicus Therapeutics Patient Advocacy
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Interessiert daran, teilzunehmen?
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.